Trials / Completed
CompletedNCT04551898
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Patients With Mild-to-Moderate COVID-19
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 181 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy of BGB-DXP593 administered intravenously as a single dose in participants with mild to moderate COVID-19
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGB-DXP593 | Intravenous (IV) infusion administered over 30 to 90 minutes at a dose as specified in the treatment arm |
| DRUG | Placebo | Placebo to match BGB-DXP593 administered as specified in the treatment arm |
Timeline
- Start date
- 2020-12-02
- Primary completion
- 2021-05-25
- Completion
- 2021-05-25
- First posted
- 2020-09-16
- Last updated
- 2024-10-26
- Results posted
- 2022-03-17
Locations
18 sites across 4 countries: United States, Brazil, Mexico, South Africa
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04551898. Inclusion in this directory is not an endorsement.